A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF INAVOLISIB COMBINED WITH A CDK4/6 INHIBITOR AND LETROZOLE VERSUS PLACEBO COMBINED WITH A CDK4/6 INHIBITOR AND LETROZOLE IN PATIENTS WITH PIK3CA-MUTANT, HORMONE RECEPTOR-POSITIVE, HER2-NEGATIVE, ADVANCED BREAST CANCER K4/6 E LETROZOLO RISPETTO A PLACEBO IN COMPOSTA CON UN INIBITORE DI CDK4/6 E LETROZOLO IN PAZIENTI CON CARCINOMA MAMMARIO AVANZATO ENDOCRINO-SENSITIVO, CON MUTAZIONE DEL GENE PIK3CA, POSITIVO AI RECETTORI ORMONALI E HER2-NEGATIVO
Phase: Phase II-III clinical trials
Principal Investigator: Dott.ssa Bianchi Giulia Valeria
Main Facility: Oncologia Medica 1
Drug: Arm A: inavolisib + letrozolo + palbociclib o ribociclib
Arm B: placebo + letrozolo + palbociclib o ribociclib
Pathologies: Breast cancer
ClinicalTrials.gov: Read more about clinical trials
A Phase III, multicenter, randomized, 1:1, double-blind, placebo-controlled study in patients with hormone-sensitive, PIK3CA-mutated, HR+, HER2-metastatic breast cancer. The study design includes two treatment arms: (ARM A, experimental arm: treated with inavolisib + letrozole + palbociclib or ribociclib – palbociclib or abemaciclib when ribociclib is not approved; ARM B, control arm: placebo + letrozole + palbociclib or ribociclib – palbociclib or abemaciclib when ribociclib is not approved).
Last update: 12/05/2026